PRISM: Phase 2 trial with panitumumab monotherapy as second‐line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

PRISM: Phase 2 trial with panitumumab monotherapy as second‐line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Authors:	Danny Rischin MD David R. Spigel MD Douglas Adkins MD Richard Wein MD Susanne Arnold MD Nimit Singhal FRACP Oliver Lee PhD Swami Murugappan MD PhD

Affiliation:	1. Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;2. Sarah Cannon Research Institute, Nashville, Tennessee;3. Washington University School of Medicine, St. Louis, Missouri;4. Department of Otolaryngology – Head and Neck Surgery, Tufts Medical Center, Boston, Massachusetts;5. University of Kentucky, Markey Cancer Center, Lexington, Kentucky;6. Royal Adelaide Hospital and University of Adelaide, Adelaide, SA, Australia;7. Amgen, South San Francisco, California;8. Amgen, Thousand Oaks, California

Abstract:

Keywords:	recurrent or metastatic squamous cell carcinoma of the head and neck panitumumab Panitumumab Regimen In Second‐line Monotherapy of Head and Neck Cancer (PRISM) trial monotherapy human papillomavirus (HPV) p16